Status:
COMPLETED
LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Conditions:
Li Fraumeni Syndrome
Eligibility:
All Genders
5-71 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the diagnostic efficacy of two follow-up schedules for the early detection of cancers in the population under study on cancer incidence at 3 years.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- P53 mutation
Exclusion
Key Trial Info
Start Date :
October 27 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 9 2017
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT01464086
Start Date
October 27 2011
End Date
October 9 2017
Last Update
February 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Gustave Roussy
Villejuif, France, 94805